An open meal-kit box holding soup and a bar on one side and laboratory glassware on the other

The pitch is clever. Proper fasting is hard, so why not eat a little — just the right foods, in just the right amounts — and trick your body into thinking it's fasting? Five days a month, a box of soups, bars and teas, and the promise of a "younger" biological age.

It's easy to file this under wellness marketing. But this diet has something most wellness products don't: randomised trials, published in serious journals. So which is it — science or marketing? Having read the papers, I think the honest answer is "both", and the useful part is knowing which bits are which.

First, what it is

The fasting-mimicking diet (FMD) is a five-day, plant-based plan: about 1,100 calories on day one and roughly 725-750 on days two to five, low in protein and sugar, higher in unsaturated fat. People usually repeat it once a month for a few months and eat normally in between. It was developed at the University of Southern California by researcher Valter Longo, and the formulations belong to USC and the company L-Nutra, which sells them as ProLon.

What the evidence shows

In generally healthy adults. The first randomised trial included 100 adults; 71 completed three monthly cycles. Compared with people on their usual diet, they lost about 2.6 kg, with less body fat, lower blood pressure and lower IGF-1, a growth-related hormone that researchers link to ageing and cancer. Blood sugar, cholesterol and an inflammation marker didn't differ between groups. The bigger benefits often quoted — in people "at risk" — came from an extra analysis done after the trial, which the authors flagged needs confirming. A quarter of FMD participants dropped out, compared with a tenth of controls (Wei et al., Science Translational Medicine, 2017).

In type 2 diabetes. This is the strongest study. In the Netherlands, 100 people with type 2 diabetes managed by their family doctors either added a monthly FMD to usual care or carried on as normal, for a year. The FMD group needed less diabetes medication, had slightly better long-term blood sugar (HbA1c down 0.3%) and lost 3.6 kg more, without losing lean mass. Glucose control improved in 53% of them, versus 8% of the comparison group. Tiredness, headaches, dizziness and nausea were common during the five-day cycles (van den Burg et al., Diabetologia, 2024).

In Crohn's disease. At Stanford, 97 people with mild-to-moderate Crohn's were randomised to three monthly cycles or their normal diet. Symptoms improved in 69% versus 44%, and 65% versus 38% reached clinical remission. Patients knew which group they were in, most had mild disease, and the trial couldn't check healing of the gut lining with a camera (Kulkarni et al., Nature Medicine, 2026).

"Biological age." A 2024 analysis of blood samples from two trials estimated that three cycles lowered participants' biological age by a median of 2.5 years, and reduced liver fat (Brandhorst et al., Nature Communications, 2024). Biological age here is a score calculated from blood tests. It's a promising marker — not proof that anyone will live longer.

Why scientists still disagree

The first sticking point is the comparison. In the three main trials above, the FMD was compared with eating as usual or usual care. That shows doing something beats doing nothing, but not whether this particular formula beats an ordinary diet with the same calories. I couldn't find a trial that tests exactly that.

The second is what's measured. Weight, blood sugar, symptom scores and biological-age estimates are meaningful, but they're stand-ins. Nobody has yet measured heart attacks, new diagnoses or lifespan.

The third is commercial ties — and here the papers themselves are the best source, because they disclose them. Valter Longo is a co-author on all four studies. Their disclosure statements say he holds equity in L-Nutra that is assigned or committed to charitable organisations, and that patents related to the diet have been filed. The 2024 diabetes paper adds that he is a founder of L-Nutra, sits on its advisory board and receives travel support from it; the 2026 Crohn's paper states he doesn't receive consulting fees. The 2017 and 2024 USC papers note that the university has licensed the intellectual property to L-Nutra and may receive royalties. In the Dutch trial, L-Nutra supplied the diet and a small part of the funding, and the funders had no role in the design or analysis. The Stanford team bought the meal boxes.

None of that means the results are wrong. Disclosure is how good science should work. It's simply part of the picture — and it's why independent replication matters so much.

What you'll hear online

"It rejuvenates your cells." That comes largely from mouse studies. In people, the only measure I found was a 30-person pilot study, sponsored by L-Nutra, which saw a possible rise in cell clean-up activity in blood cells at some time points but not all (Espinoza et al., GeroScience, 2025).

"It takes years off your age." It lowered a blood-based age estimate in two trials. That's a good reason for more research, not a guarantee.

Before believing any fasting claim, it helps to ask five quick questions:

Five questions before you believe a fasting claim

  1. Was this seen in people, or in mice?
  2. How many people, and for how long?
  3. Compared to what?
  4. Did they measure a real outcome, or a number in the blood?
  5. Does the person telling me this sell something related? (Not an accusation — just useful to know.)

For fasting-mimicking diets, questions three, four and five all come into play — which is exactly why the papers are worth reading in full.

What would actually settle it

An independently funded trial comparing the FMD with a home-made diet of the same calories, running for years and tracking real outcomes: new diabetes diagnoses, heart events, Crohn's flares confirmed by endoscopy. It's a clear, answerable question, and well worth funding.

What you can do

If you're curious, the strongest evidence is for people with type 2 diabetes treated with metformin or diet alone — and that trial ran inside routine care, alongside their doctors. If you take diabetes medication, especially insulin or other tablets that can cause low blood sugar, don't start a five-day low-calorie programme without your doctor. See Before you fast on medication: the questions to ask your doctor and Fasting with type 2 diabetes: can it work as well as a tablet?.

So: science or marketing? Real trials, real results, real commercial interests, all published side by side. The most honest place to stand is curious — and waiting for the comparison that hasn't been run yet.

— Dr. Brugal

Voices in the debate

If you'd like to hear the case for fasting-mimicking diets from the people who developed and champion them, these are the key voices. Their views often go beyond what published human trials have shown so far — which is exactly why it's worth hearing them and checking the studies side by side.

  • Prof Valter Longo — researcher (PhD) at the University of Southern California who developed the fasting-mimicking diet and founded L-Nutra, the company behind ProLon.
  • Dr Joseph Antoun — MD PhD MPP, CEO of L-Nutra, the company behind ProLon. Aging Well podcast, ep. 192
  • Prof Andreas Michalsen — MD PhD, internal and nutritional medicine at Charité Berlin, a co-author of the 2017 trial and an advocate of therapeutic fasting; author of The Fasting Fix. Penguin Random House

For the wider debate, see our series guide: Why scientists still can't agree on fasting — and what would settle it.

References

All studies retrieved via PubMed. Disclosure statements quoted from each paper's full text on PubMed Central.

  1. Wei M, Brandhorst S, Shelehchi M, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Science Translational Medicine. 2017;9(377):eaai8700. Randomised crossover trial, 100 generally healthy adults, 3 months. doi:10.1126/scitranslmed.aai8700 (PMID 28202779)
  2. van den Burg EL, Schoonakker MP, van Peet PG, et al. Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial. Diabetologia. 2024;67(7):1245-1259. Randomised controlled trial, 100 people with type 2 diabetes, 12 months. doi:10.1007/s00125-024-06137-0 (PMID 38546821)
  3. Kulkarni C, Fardeen T, Gubatan J, et al. A fasting-mimicking diet in patients with mild-to-moderate Crohn's disease: a randomized controlled trial. Nature Medicine. 2026;32(3):1023-1033. Open-label randomised controlled trial, 97 people with Crohn's disease, 3 months. doi:10.1038/s41591-025-04173-w (PMID 41530382)
  4. Brandhorst S, Levine ME, Wei M, et al. Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications. 2024;15(1):1309. Secondary and exploratory analysis of two clinical trials, humans (with background mouse data). doi:10.1038/s41467-024-45260-9 (PMID 38378685)
  5. Espinoza SE, Park S, Connolly G, et al. Effect of fasting-mimicking diet on markers of autophagy and metabolic health in human subjects. GeroScience. 2025 (online); 2026;48(5):7083-7093. Pilot randomised trial, 30 healthy adults, 8 days; sponsored by L-Nutra. doi:10.1007/s11357-025-02035-4 (PMID 41372565)

Awareness content — not medical advice. Always talk to your doctor or pharmacist before making changes.